Cançado, Rodolfo <br/><br/>
Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.  [electronic resource] 

 -  European journal of haematology  Dec 2015 
 - 545-50 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1600-0609 
<br/><br/><label>Standard No.: </label>10.1111/ejh.12530  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzoates--administration & dosage<br/>Biomarkers<br/>Deferasirox<br/>Erythrocyte Indices<br/>Female<br/>Hemochromatosis--complications<br/>Hemochromatosis Protein<br/>Histocompatibility Antigens Class I--genetics<br/>Humans<br/>Iron Chelating Agents--administration & dosage<br/>Iron Overload--diagnosis<br/>Male<br/>Membrane Proteins--genetics<br/>Middle Aged<br/>Mutation<br/>Time Factors<br/>Treatment Outcome<br/>Triazoles--administration & dosage